Venous angioplasty for "CCSVI" in multiple sclerosis
Ending a therapeutic misadventure In 1889, Charcot described the results of "suspension therapy" for tabes dorsalis and other diseases. 1 The procedure entailed suspending patients from a harness attached to their chin and occiput for several minutes. The goal was to stretch the spinal cord, presumably to improve circulation. Charcot described several patients with tabes dorsalis whose symptoms improved following the treatment. However, the therapy was often painful, one patient with multiple sclerosis (MS) developed paraplegia after 2 treatments, and there were other serious side effects, including death by strangulation. Despite his initial enthusiasm for the treatment, Charcot eventually abandoned suspension therapy, displaying the wisdom to recognize a treatment that did not result in sustained benefit and carried serious risks.
In this issue of Neurology ® , Siddiqui et al. They reported clinical improvement primarily among the 35 subjects who had relapsing-remitting MS in whom there was an increased proportion of participants who were relapse-free and a reduction in proportion of participants with brain MRI gadolinium-enhancing lesions following transluminal angioplasty. 4 Despite the lack of adequate controls and blinding, word of these results spread rapidly through lay print, electronic, and social media and raised the hopes of many people with MS, leading some to advocate vigorously for provision of this seemingly effective treatment for MS. 5 In response, the US and Canadian MS Societies jointly committed over $2.4 million for research to determine whether people with MS had cerebrospinal venous abnormalities. Concurrently, some interventional radiologists in the United States, Canada, and elsewhere began to treat patients with MS ad libitum with venous angioplasty with and without stenting, occasionally with tragic consequences. 6 Now Siddiqui et al. report on a randomized, double-blind trial comparing venous angioplasty with sham angioplasty in 19 participants with MS who met the Zamboni Doppler flow criteria for CCSVI. These patients were randomized to undergo balloon angioplasty (n 5 9) or sham angioplasty (n 5 10). Participants and personnel evaluating responses remained blinded to the treatment participants received. While there were no notable complications from the venous angioplasty, there was no evidence of clinical improvement in participants undergoing venous angioplasty compared with those receiving sham angioplasty. However, 5 of 9 participants receiving venous angioplasty had evidence of increased disease activity by brain MRI compared with 2 of 10 participants undergoing sham treatment. Importantly, improvements occurred in some subjective outcome measures in the sham-treated participants, such as measures of fatigue and quality of life, suggesting that the subjective positive outcomes reported by participants in unblinded, open-label studies might represent placebo effects. Siddiqui et al. concluded that venous angioplasty did not result in clinical improvement and increased venous flow might increase disease activity in some patients with MS. While this study was small, it is the first double-blind sham angioplasty-controlled trial of venous angioplasty in MS and the results do not support a larger trial of this treatment.
Multiple research groups have failed to find evidence of cerebrospinal venous flow or anatomic abnormalities in MS. [7] [8] [9] This has cast serious doubts on the validity of CCSVI as a pathologic entity in MS. Thus, the rationale for venous angioplasty as a treatment for MS is flawed. Of course a therapy can be beneficial even if the theory about how it works is wrong. A Cochrane review of reports of clinical trials for percutaneous transluminal angioplasty for CCSVI in people with MS found major methodologic problems with all trials published prior to June 2012. 10 The authors emphasized that randomized, double-blind, controlled clinical trials with objective outcomes needed to be conducted before any conclusions about the effectiveness of this procedure could be made. The clinical trial that Siddiqui et al. conducted met these requirements and failed to show any benefit to the procedure. So the theory of CCSVI is wrong and, when an appropriately blinded and controlled trial of venous angioplasty was performed, there was no evidence of benefit.
What happens now with CCSVI and venous angioplasty for MS? Interventional radiologists should cease subjecting people with MS to venous angioplasty and charging patients and private and governmental insurance programs for this ineffective treatment that is based on an incorrect theory. We also question the ethics of continuing to conduct clinical trials of venous angioplasty for CCSVI. Clinical equipoise requires that uncertainty exists about the efficacy of an intervention being studied in a clinical trial. Since there is substantial evidence indicating that CCSVI is not a disorder and there is now a well-controlled double-blind clinical trial showing no benefit to venous angioplasty, there is no longer equipoise. Clinical trials of venous angioplasty for MS are placing participants at risk of complications without a reasonable hope of benefit.
Despite initial encouraging results from an uncontrolled and unblinded trial, Charcot was wise enough to eventually abandon the use of suspension therapy. The treatment was founded on a faulty theory of pathogenesis, did not result in sustained benefits, and carried risks. The same can be said of CCSVI and venous angioplasty for MS. It is time for us to show the same wisdom that Charcot displayed.
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